GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
GLP-1 weight-loss drugs carry a previously underrecognized hair loss risk, helping doctors prepare patients and researchers explore prevention strategies.
A systematic review of 24 studies confirms a pharmacovigilance and clinical signal for hair loss with GLP-1 receptor agonists, particularly semaglutide and tirzepatide, with telogen effluvium being the predominant subtype and dose-dependence evident for semaglutide. This adverse effect counseling gap is increasingly important as GLP-1 prescribing expands to obesity treatment at higher doses.
What the study was
- Study design
- Systematic review (PRISMA; 24 studies from 133 screened)
- Population
- Patients receiving GLP-1 receptor agonist therapies (semaglutide, tirzepatide, liraglutide, dulaglutide)
- Category
- Public Health
- Maturity
- Validated
- Journal
- Science Progress
Why it surfaced
Systematic review with pharmacovigilance relevance for millions of GLP-1 RA users; dose-dependent and demographic risk factors identified, with direct counseling implications.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.